GILD vs. AMGN, VRTX, REGN, ALNY, BIIB, UTHR, EXEL, INCY, NBIX, and BMRN
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Exelixis (EXEL), Incyte (INCY), Neurocrine Biosciences (NBIX), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.
Gilead Sciences vs.
Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
Gilead Sciences presently has a consensus target price of $110.55, indicating a potential upside of 1.88%. Amgen has a consensus target price of $309.22, indicating a potential upside of 12.07%. Given Amgen's higher possible upside, analysts plainly believe Amgen is more favorable than Gilead Sciences.
In the previous week, Gilead Sciences had 8 more articles in the media than Amgen. MarketBeat recorded 46 mentions for Gilead Sciences and 38 mentions for Amgen. Gilead Sciences' average media sentiment score of 1.31 beat Amgen's score of 1.11 indicating that Gilead Sciences is being referred to more favorably in the media.
Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.
Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.9%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.5%. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences received 926 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 71.71% of users gave Amgen an outperform vote.
Gilead Sciences has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Summary
Gilead Sciences and Amgen tied by winning 11 of the 22 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Gilead Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:GILD) was last updated on 5/20/2025 by MarketBeat.com Staff